FDA Approves TOLVAPTAN — Teva Pharmaceuticals, Inc.
Teva Pharmaceuticals announced Thursday the FDA approval of its tolvaptan ANDA, positioning the company to compete in the market for this treatment. This approval is anticipated to accelerate revenue growth for Teva, benefiting from the projected patent expiration of the reference brand drug.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed